The first cord blood transplantation (CBT) was performed in a 5-year-old bo
y with acute mylogenous leukemia from his HLA-identical sibling donor in 19
94, Since then there have been 17 related and 131 unrelated CBTs in Japan.
Overall survival and disease-free survival (DFS) were over 70% in sibling d
onor CBT, DFS of unrelated CBT in leukemia and other hematological malignan
cies was 43%, and OS of UCBT in non-malignant diseases was 63%, HLA dispari
ty between the donor and the recipient did not affect the incidence and sev
erity of acute graft-versus-host disease (GVHD) or survival, Cell dose was
the most important factor for engraftment and survival both in malignant an
d in nonmalignant diseases. The Japanese government has recently establishe
d the nationwide cord blood bank network, and eight local cord blood hanks
are financially supported by the government. 20 000 units of CB are planned
to be collected and stored in the next 5 years by this network.